Vosoritide
Contents
Description
Vosoritide is a biologic analog of C-type natriuretic peptide (CNP) designed to promote bone growth by stimulating endochondral ossification. It is approved for the treatment of achondroplasia in pediatric patients aged 5 years and older with open epiphyses. While SADDAN is a severe form related to FGFR3 mutations similar to achondroplasia, vosoritide's mechanism may have theoretical relevance, though it is not specifically approved for SADDAN.
Indications & Therapeutic Use
achondroplasia in pediatric patients with open epiphyses
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Vosoritide — GNH India
10 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Vosoritide products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | vosoritide |
| Brands | 1 brand available |
| Active Ingredient | vosoritide |
| Drug Class | achondroplasia in pediatric patients with open epiphyses |
| Manufacturer | BioMarin Pharmaceutical |
| Dosage Forms | subcutaneous injection, 0.4mg, 0.56mg, 1.2mg vials |
| Medical Code | M09AX09 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 21 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT03197766 |
| Countries | 8 countries |